{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:11:59Z","timestamp":1793052719413,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Sodium-glucose co-transporter-2 inhibitors (SGLT2is) are widely used in clinical practice for their demonstrated cardiorenal benefits, but multiple adverse events (AEs) have been reported. We aimed to describe the distribution of SGLT2i-related AEs in different systems and identify important medical event (IME) signals for SGLT2i.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Data from the first quarter (Q1) of 2013\u20132021 Q2 in FAERS were selected to conduct disproportionality analysis. The definition of AEs and IMEs relied on the system organ classes (SOCs) and preferred terms (PTs) by the Medical Dictionary for Regulatory Activities (MedDRA-version 24.0). Two signal indicators, the reported odds ratio (ROR) and information component (IC), were used to estimate the association between SGLT2is and IMEs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 57,818 records related to SGLT2i, with 22,537 SGLT2i-IME pairs. Most SGLT2i-related IMEs occurred in monotherapy (<jats:italic>N<\/jats:italic> = 21,408, 94.99%). Significant signals emerged at the following SOCs: \u201cmetabolism and nutrition disorders\u201d (<jats:italic>N<\/jats:italic> = 9,103; IC025 = 4.26), \u201crenal and urinary disorders\u201d (3886; 1.20), \u201cinfections and infestations\u201d (3457; 0.85). The common strong signals were observed in diabetic ketoacidosis, ketoacidosis, euglycaemic diabetic ketoacidosis and Fournier\u2019s gangrene. Unexpected safety signals such as cellulitis, osteomyelitis, cerebral infarction and nephrolithiasis were detected.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our pharmacovigilance analysis showed that a high frequency was reported for IMEs triggered by SGLT2i monotherapy. Different SGLT2is caused different types and the association strengths of IMEs, while they also shared some specific PTs. Most of the results are generally consistent with previous studies, and more pharmacoepidemiological studies are needed to validate for unexpected AEs. Based on risk-benefit considerations, clinicians should be well informed about important medical events that may be aggravated by SGLT2is.<\/jats:p>","DOI":"10.3389\/fphar.2021.766125","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T08:11:40Z","timestamp":1639987900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel Statistical Tools for Monitoring the Safety of Marketed Drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021","volume":"44","author":"American Diabetes","year":"2021","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2924","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis Associated with SGLT2 Inhibitor Treatment: Analysis of FAERS Data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 Inhibitors and Atrial Fibrillation in the Food and Drug Administration Adverse Event Reporting System","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.2337\/dc20-2492","article-title":"Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses from DECLARE-TIMI 58","volume":"44","author":"Cahn","year":"2021","journal-title":"Dia Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s13300-021-01004-2","article-title":"Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies","volume":"12","author":"Caparrotta","year":"2021","journal-title":"Diabetes Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105530","DOI":"10.1016\/j.phrs.2021.105530","article-title":"Sodium-glucose Transporter 2 Inhibitors for Renal and Cardiovascular Protection in US Adults with Type 2 Diabetes: Impact of the 2020 KDIGO Clinical Practice Guidelines","volume":"166","author":"Ciardullo","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/s2213-8587(17)30257-7","article-title":"SGLT2 Inhibitors and Amputations in the US FDA Adverse Event Reporting System","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 Inhibitors and Diabetic Ketoacidosis: Data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e000725","DOI":"10.1136\/bmjdrc-2019-000725","article-title":"Pharmacovigilance Assessment of the Association Between Fournier's Gangrene and Other Severe Genital Adverse Events with SGLT-2 Inhibitors","volume":"7","author":"Fadini","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/03007995.2017.1392293","article-title":"Safety and Efficacy of Canagliflozin in Elderly Patients with Type 2 Diabetes Mellitus: A 1-year Post-marketing Surveillance in Japan","volume":"34","author":"Goda","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3695101","DOI":"10.1155\/2020\/3695101","article-title":"Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System","volume":"2020","author":"Hu","year":"2020","journal-title":"J. Diabetes Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1080\/14656566.2016.1232395","article-title":"SGLT2 Inhibitors in the Pipeline for the Treatment of Diabetes Mellitus in Japan","volume":"17","author":"Ito","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11914-020-00609-z","article-title":"Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits","volume":"18","author":"Jackson","year":"2020","journal-title":"Curr. Osteoporos. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/5584_2020_479","article-title":"Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"1307","author":"Kuchay","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5604\/01.3001.0013.5894","article-title":"Fournier's Gangrene - Challenge for Surgeon","volume":"92","author":"Kuchinka","year":"2019","journal-title":"Pol. Przegl Chir"},{"key":"B24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40264-017-0611-5","article-title":"Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System","volume":"41","author":"Min","year":"2018","journal-title":"Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and Strengths of the Disproportionality Analysis for Identification of Adverse Drug Reactions in a Pharmacovigilance Database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage Observed-To-Expected Ratios for Robust and Transparent Large-Scale Pattern Discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat. Methods Med. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 Inhibitors and the Risk of Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2020.03.019","article-title":"Acute Kidney Injury Events in Patients with Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study","volume":"76","author":"Rampersad","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","article-title":"Adverse Events with Sodium-Glucose Co-transporter-2 Inhibitors: A Global Analysis of International Spontaneous Reporting Systems","volume":"27","author":"Raschi","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An Update on the Safety of SGLT2 Inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/dom.13965","article-title":"What Have We Learned About Renal protection from the Cardiovascular Outcome Trials and Observational Analyses with SGLT2 Inhibitors?","author":"Sridhar","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s2213-8587(19)30154-8","article-title":"SGLT2 Inhibitors as Adjunctive Therapy for Type 1 Diabetes: Balancing Benefits and Risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 Inhibitors on Cardiovascular, Renal and Safety Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","article-title":"SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation","volume":"77","author":"Tuttle","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium Glucose Cotransporter 2 Inhibitors and Risk of Serious Adverse Events: Nationwide Register Based Cohort Study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s13300-020-00771-8","article-title":"SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study","volume":"11","author":"Wang","year":"2020","journal-title":"Diabetes Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1515\/jpem-2015-0056","article-title":"Cerebral Infarction and Femoral Venous Thrombosis Detected in a Patient with Diabetic Ketoacidosis and Heterozygous Factor V Leiden G1691A and PAI-1 4G\/5G Mutations","volume":"28","author":"Yaroglu Kazanci","year":"2015","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/FJC.0000000000001018","article-title":"Effects of SGLT2 Inhibitor on Ischemic Events Stemming from Atherosclerotic Coronary Diseases: A Systematic Review and Meta-Analysis with Trial Sequential Analysis of Randomized Controlled Trials","volume":"77","author":"Ye","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine Toxicity of Immune Checkpoint Inhibitors: A Real-World Study Leveraging US Food and Drug Administration Adverse Events Reporting System","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","article-title":"Canagliflozin and Fracture Risk in Individuals with Type 2 Diabetes: Results from the CANVAS Program","volume":"62","author":"Zhou","year":"2019","journal-title":"Diabetologia"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.766125\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T08:11:49Z","timestamp":1639987909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.766125\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":36,"alternative-id":["10.3389\/fphar.2021.766125"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.766125","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"article-number":"766125"}}